Boehringer Ingelheim and Lilly Announce an Academic Collaboration with University of Oxford to Investigate the Effects of Empagliflozin in People with Chronic Kidney Disease
• University of Oxford to assess effect of empagliflozin on heart and kidney disease in people with chronic kidney disease

• EMPA-KIDNEY will be part of the empagliflozin clinical development programme which explores the efficacy and safety of empagliflozin across a broad spectrum of patients and clinical conditions